Cargando…

A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients

With growing numbers of elderly multiple myeloma patients, reliable tools to assess their vulnerability are required. The objective of the analysis herein was to develop and validate an easy to use myeloma risk score (revised Myeloma Comorbidity Index) that allows for risk prediction of overall surv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Engelhardt, Monika, Domm, Anne-Saskia, Dold, Sandra Maria, Ihorst, Gabriele, Reinhardt, Heike, Zober, Alexander, Hieke, Stefanie, Baayen, Corine, Müller, Stefan Jürgen, Einsele, Hermann, Sonneveld, Pieter, Landgren, Ola, Schumacher, Martin, Wäsch, Ralph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477610/ https://www.ncbi.nlm.nih.gov/pubmed/28154088 http://dx.doi.org/10.3324/haematol.2016.162693

Ejemplares similares

Validation of the Revised Myeloma Comorbidity Index and other comorbidity scores in a multicenter German study group multiple myeloma trial
por: Dold, Sandra Maria, et al.
Publicado: (2020)

Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM–comorbidity score
por: Kleber, M, et al.
Publicado: (2011)

An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence
por: Holler, Maximilian, et al.
Publicado: (2022)

Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma
por: Dold, Sandra Maria, et al.
Publicado: (2020)

Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients
por: Riebl, Veronika, et al.
Publicado: (2021)

Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life
por: Greil, Christine, et al.
Publicado: (2019)

European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma
por: Bruno, Benedetto, et al.
Publicado: (2021)

Allogeneic Stem Cell Transplantation in Multiple Myeloma
por: Greil, Christine, et al.
Publicado: (2021)

Proteasome inhibition: the dawn of novel therapies in multiple myeloma
por: Engelhardt, Monika, et al.
Publicado: (2022)

Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age
por: Engelhardt, Monika, et al.
Publicado: (2020)

Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors
por: Gengenbach, Laura, et al.
Publicado: (2021)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany
por: Engelhardt, Monika, et al.
Publicado: (2020)

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
por: Gay, Francesca, et al.
Publicado: (2018)

Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
por: Bringhen, Sara, et al.
Publicado: (2018)

Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
por: Shoumariyeh, Khalid, et al.
Publicado: (2021)

Biological determinants of health disparities in multiple myeloma
por: Smith, Cheryl Jacobs, et al.
Publicado: (2018)

Management of multiple myeloma during COVID-19 pandemic
por: Jethava, YS, et al.
Publicado: (2020)

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
por: Caers, Jo, et al.
Publicado: (2018)

Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast
por: Landgren, Ola, et al.
Publicado: (2023)

Two cases of carfilzomib‐induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma
por: Rassner, Michael, et al.
Publicado: (2021)

Geriatric assessments and frailty scores in multiple myeloma patients: a needed tool for individualized treatment?
por: Möller, Mandy-Deborah, et al.
Publicado: (2021)

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2020)

Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis
por: Wäsch, Ralph, et al.
Publicado: (2023)

Intratibial Injection of Human Multiple Myeloma Cells in NOD/SCID IL-2Rγ(Null) Mice Mimics Human Myeloma and Serves as a Valuable Tool for the Development of Anticancer Strategies
por: Schueler, Julia, et al.
Publicado: (2013)

Novel immunotherapies in multiple myeloma – chances and challenges
por: Rasche, Leo, et al.
Publicado: (2021)

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
por: Terpos, Evangelos, et al.
Publicado: (2020)

Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
por: Landgren, Ola, et al.
Publicado: (2016)

COVID-19 AND MYELOMA
por: Ludwig, H, et al.
Publicado: (2022)

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
por: Davies, Faith E., et al.
Publicado: (2022)

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2021)

Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
por: Terpos, Evangelos, et al.
Publicado: (2023)

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network
por: Moreau, Philippe, et al.
Publicado: (2019)

2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde
por: Musto, Pellegrino, et al.
Publicado: (2021)

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2018)

Fractures and survival in multiple myeloma: results from a population-based study
por: Thorsteinsdottir, Sigrun, et al.
Publicado: (2020)

Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab
por: Einsele, Hermann, et al.
Publicado: (2016)

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
por: Boyle, Eileen M., et al.
Publicado: (2021)

Incidence of multiple myeloma in Great Britain, Sweden, and Malmö, Sweden: the impact of differences in case ascertainment on observed incidence trends
por: Vélez, Ramón, et al.
Publicado: (2016)

Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma
por: Zhou, Xiang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h3eavmbd886s7vjib6b3clatl6